Newsfiscal.ai
Artiva Biotherapeutics Announces Workforce Reduction and Strategic Alternatives Review
· Published
Article summary
Artiva Biotherapeutics is laying off 94% of its workforce and evaluating strategic alternatives following the death of two patients in a Phase IIa clinical trial.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…